Journal Article

Race and Outcomes to 177LuLu-PSMA-617 in Advanced Prostate Cancer

Stoltenberg, Hailey, Gallagher, John, Rami, Avina, Khorasanchi, Adam, Ng, Thomas S. C., Gopalakrishan, Dharmesh, Jacene, Heather, Zhong, Caiwei, Gafita, Andrei, Childs, Daniel S., Muniz, Miguel, Fein, Daniel, Voter, Andrew F., Xie, Wanling, Ravi, Praful, Mohammadi, Sedra, Yang, Yuanquan

2025

Overview

Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [177Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA. The primary outcomes were PSA-50 rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Statistical models were adjusted for age, number of prior therapies, sites of metastases, and baseline PSA. A total of 654 patients were included; 593 (91%) were White, 45 (7%) were Black and 16 (2%) were another non-Black minority (NBM). There were no statistically significant differences in PSA-50 rates, PSA-PFS and OS between the groups. Black and White patients treated with LuPSMA had similar clinical outcomes; efforts are needed to ensure Black and NBM patients have equal access to life prolonging therapies to narrow disparities in outcomes.

• Publisher: MDPI AG,MDPI
• Subject: Androgens / Black people / Cancer / Cancer therapies / Chemotherapy / Clinical outcomes / Clinical trials / Communication / Health care access / Hispanic Americans / Inequality / Medical prognosis / Metastases / Metastasis / Mortality / Patients / Prostate cancer / Race / Racial differences / Statistical analysis / Statistical models